A protocol for a trial of homeopathic treatment for irritable bowel syndrome

被引:6
|
作者
Peckham, Emily J. [1 ]
Relton, Clare [2 ]
Raw, Jackie [3 ]
Walters, Clare [3 ]
Thomas, Kate [2 ]
Smith, Christine [3 ]
机构
[1] Univ Leeds, Sch Healthcare, Leeds, W Yorkshire, England
[2] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England
[3] Barnsley Hosp NHS Fdn Trust, Barnsley, S Yorkshire, England
来源
BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE | 2012年 / 12卷
关键词
Irritable bowel syndrome; Homeopathic treatment; Attention control; Randomised controlled trial; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; COGNITIVE-BEHAVIORAL THERAPY; CONSULTATION PROCESS; PRIMARY-CARE; PLACEBO; OUTCOMES; INTERVENTION; VALIDATION; MANAGEMENT;
D O I
10.1186/1472-6882-12-212
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background: Irritable bowel syndrome is a chronic condition with no known cure. Many sufferers seek complementary and alternative medicine including homeopathic treatment. However there is much controversy as to the effectiveness of homeopathic treatment. This three-armed study seeks to explore the effectiveness of individualised homeopathic treatment plus usual care compared to both an attention control plus usual care and usual care alone, for patients with irritable bowel syndrome. Methods/design: This is a three-armed pragmatic randomised controlled trial using the cohort multiple randomised trial methodology. Patients are recruited to an irritable bowel syndrome cohort from primary and secondary care using GP databases and consultants lists respectively. From this cohort patients are randomly selected to be offered, 5 sessions of homeopathic treatment plus usual care, 5 sessions of supportive listening plus usual care or usual care alone. The primary clinical outcome is the Irritable Bowel Syndrome Symptom Severity at 26 weeks. From a power calculation, it is estimated that 33 people will be needed for the homeopathic treatment arm and 132 for the usual care arm, to detect a minimal clinical difference at 80 percent power and 5 percent significance allowing for loss to follow up. An unequal group size has been used for reasons of cost. Analysis will be by intention to treat and will compare homeopathic treatment with usual care at 26 weeks as the primary analysis, and homeopathic treatment with supportive listening as an additional analysis. Discussion: This trial has received NHS approval and results are expected in 2013.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial
    van Tilburg, Miranda A. L.
    Palsson, Olafur S.
    Ringel, Yehuda
    Whitehead, William E.
    COMPLEMENTARY THERAPIES IN MEDICINE, 2014, 22 (01) : 17 - 20
  • [32] Asimadoline in the treatment of irritable bowel syndrome
    Mangel, Allen W.
    Williams, Valerie S. L.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (10) : 1257 - 1264
  • [33] Targeting the gut microbiota for the treatment of irritable bowel syndrome
    Herndon, Charles C.
    Wang, Yen-Po
    Lu, Ching-Liang
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2020, 36 (03) : 160 - 170
  • [34] Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment (The ATLANTIS trial): protocol for a randomised double-blind placebo-controlled trial in primary care
    Sarah L. Alderson
    Alexandra Wright-Hughes
    Alexander C. Ford
    Amanda Farrin
    Suzanne Hartley
    Catherine Fernandez
    Christopher Taylor
    Pei Loo Ow
    Emma Teasdale
    Daniel Howdon
    Elspeth Guthrie
    Robbie Foy
    Matthew J. Ridd
    Felicity L. Bishop
    Delia Muir
    Matthew Chaddock
    Amy Herbert
    Deborah Cooper
    Ruth Gibbins
    Sonia Newman
    Heather Cook
    Roberta Longo
    Hazel Everitt
    Trials, 23
  • [35] A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea
    Garsed, Klara
    Chernova, Julia
    Hastings, Margaret
    Lam, Ching
    Marciani, Luca
    Singh, Gulzar
    Henry, Amanda
    Hall, Ian
    Whorwell, Peter
    Spiller, Robin
    GUT, 2014, 63 (10) : 1617 - +
  • [36] A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome
    Hoveyda, Nourieh
    Heneghan, Carl
    Mahtani, Kamal R.
    Perera, Rafael
    Roberts, Nia
    Glasziou, Paul
    BMC GASTROENTEROLOGY, 2009, 9
  • [37] Effectiveness of vitamin D for irritable bowel syndrome A protocol for a systematic review of randomized controlled trial
    Shi, Sheng-Mei
    Wen, Yan-Li
    Hou, Hai-Bin
    Liu, Hai-Xia
    MEDICINE, 2019, 98 (09) : 1 - 4
  • [38] Efficacy of Zemedy, a Mobile Digital Therapeutic for the Self-management of Irritable Bowel Syndrome: Crossover Randomized Controlled Trial
    Hunt, Melissa
    Miguez, Sofia
    Dukas, Benji
    Onwude, Obinna
    White, Sarah
    JMIR MHEALTH AND UHEALTH, 2021, 9 (05):
  • [39] Probiotics use to treat irritable bowel syndrome
    Hosseini, Asieh
    Nikfar, Shekoufeh
    Abdollahi, Mohammad
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (10) : 1323 - 1334
  • [40] An Open-Label Trial Study of Quality-of-Life Assessment in Irritable Bowel Syndrome and Their Treatment
    Alexandru, Bogdana Ariana
    Rat, Lavinia Alina
    Moldovan, Andrada Florina
    Mihancea, Petru
    Maris, Lavinia
    MEDICINA-LITHUANIA, 2022, 58 (06):